Anti- or pro-proliferation - Conditional options for TGF-α and cetuximab in head and neck squamous cell carcinoma.

Lars Ekblad; Charlotte Welinder; Elisabeth Kjellén; Eva Brun; Johan Wennerberg

doi:10.1016/j.oraloncology.2014.08.019

Anti- or pro-proliferation - Conditional options for TGF-α and cetuximab in head and neck squamous cell carcinoma.

Lars Ekblad, Charlotte Welinder, Elisabeth Kjellén, Eva Brun, Johan Wennerberg

Skåne University Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

Cetuximab is an epidermal growth factor receptor (EGFR)-targeting drug that has shown effects in head and neck squamous cell carcinoma (HNSCC). The effects are, however, small and have mainly been proven in a subset of patients, and the cost-effectiveness has been questioned. For this reason, we need to know more about the basic mechanisms controlling the effect of EGFR signalling on tumour growth.

Original language	English
Pages (from-to)	46-52
Journal	Oral Oncology
Volume	51
Issue number	1
DOIs	https://doi.org/10.1016/j.oraloncology.2014.08.019
Publication status	Published - 2015

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.oraloncology.2014.08.019

http://www.ncbi.nlm.nih.gov/pubmed/25261297?dopt=Abstract

Cite this

@article{3b36f7729bc04d5bb3eda61bb2cbda05,

title = "Anti- or pro-proliferation - Conditional options for TGF-α and cetuximab in head and neck squamous cell carcinoma.",

abstract = "Cetuximab is an epidermal growth factor receptor (EGFR)-targeting drug that has shown effects in head and neck squamous cell carcinoma (HNSCC). The effects are, however, small and have mainly been proven in a subset of patients, and the cost-effectiveness has been questioned. For this reason, we need to know more about the basic mechanisms controlling the effect of EGFR signalling on tumour growth.",

author = "Lars Ekblad and Charlotte Welinder and Elisabeth Kjell{\'e}n and Eva Brun and Johan Wennerberg",

year = "2015",

doi = "10.1016/j.oraloncology.2014.08.019",

language = "English",

volume = "51",

pages = "46--52",

journal = "Oral Oncology",

issn = "1879-0593",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Anti- or pro-proliferation - Conditional options for TGF-α and cetuximab in head and neck squamous cell carcinoma.

AU - Ekblad, Lars

AU - Welinder, Charlotte

AU - Kjellén, Elisabeth

AU - Brun, Eva

AU - Wennerberg, Johan

PY - 2015

Y1 - 2015

N2 - Cetuximab is an epidermal growth factor receptor (EGFR)-targeting drug that has shown effects in head and neck squamous cell carcinoma (HNSCC). The effects are, however, small and have mainly been proven in a subset of patients, and the cost-effectiveness has been questioned. For this reason, we need to know more about the basic mechanisms controlling the effect of EGFR signalling on tumour growth.

AB - Cetuximab is an epidermal growth factor receptor (EGFR)-targeting drug that has shown effects in head and neck squamous cell carcinoma (HNSCC). The effects are, however, small and have mainly been proven in a subset of patients, and the cost-effectiveness has been questioned. For this reason, we need to know more about the basic mechanisms controlling the effect of EGFR signalling on tumour growth.

U2 - 10.1016/j.oraloncology.2014.08.019

DO - 10.1016/j.oraloncology.2014.08.019

M3 - Article

C2 - 25261297

SN - 1879-0593

VL - 51

SP - 46

EP - 52

JO - Oral Oncology

JF - Oral Oncology

IS - 1

ER -

Anti- or pro-proliferation - Conditional options for TGF-α and cetuximab in head and neck squamous cell carcinoma.

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Cite this